**Editorial**

Drug target identification is a key step in the development of effective therapeutic agents. In this issue, we present the current status of some validated and potential targets in drug discovery for developing therapeutic agents for the treatment of cancer, inflammation, cardiovascular diseases, neurodegenerative diseases, HIV, and influenza A virus. I am indebted to my colleagues for their cooperation and efforts to find time from their busy schedule to contribute to this issue. Also I would like to thank, on behalf of all the contributors, the journal for providing us an opportunity to share our thoughts on these interesting topics and hope this issue will benefit research scientists in their pursues related to these topics.

The first article, from Binghe Wang and colleagues, describes the recent development in making prodrugs of pharmaceutically acceptable forms of therapeutic hydrogen sulfide. Recent years have seen a significantly increased level of interests in gaseous signaling molecules, which include nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide. These molecules are produced endogenously and play key regulatory roles in mammals. Naturally, they are also excellent targets for the development of therapeutics. One key challenge in developing gaseous molecules as therapeutics is in their safe and controlled delivery. Prodrug is a very effective approach to address this challenge.

Cancer metastasis is the primary cause of morbidity and mortality, and responsible for about 90% of cancer deaths. Although cancer survival rate has been significantly improved over the years, the improvement is primarily due to early diagnosis and cancer growth inhibition. Limited progress has been made in the treatment of cancer metastasis. Xiangming Guan provides an overview of the metastatic process with a focus on the four essential steps (detachment, migration, invasion and adhesion), related biochemical parameters, and targets for metastasis prevention and inhibition.

Related to cancer treatment, hypoxia-inducible factor-1 (HIF-1) has been recognized for two decades to play a significant role in cancer growth and metastasis. Its selective expression in solid tumor has made it an attractive target for the development of anticancer agents. Wei Li and Georgina N Masoud provide an overview of the current status of HIF-1, its related regulatory pathway, and targets for anticancer drug development.

Oxidative stress has been associated with a number of pathological conditions such as inflammation, neurodegenerative diseases, cardiovascular diseases, diabetes, cancer, and etc. The antioxidant enzyme system protects cells against oxidative stress through elevating a number of cytoprotective oxidative stress response enzymes. Longqin Hu and colleagues provide a review on a protein-protein interaction (PPI) (the Keap1--Nrf2 protein--protein interaction) that affects the expression of these cytoprotective oxidative stress response enzymes, and inhibition of the PPI to increase the expression of these enzymes. Screening methods for developing the inhibitors of the PPI are also presented.

Two reviews are devoted to viral infections. One is provided by Wei Wang and colleagues with a focus on Influenza A. Influenza A virus causes seasonal or pandemic flu, which remains as one of the major plagues worldwide with high morbidity and significant mortality. The increasing frequency of viral resistance to the current clinically used anti-influenza virus drugs, particularly to amantadine and oseltamivir, underlines an urgent need for novel antiviral drugs against resistant influenza A virus. Wei Wang and colleagues present a brief review of the molecular mechanism behind the resistance and discuss recent progresses and potential strategies in developing new small-molecule compounds to overcome influenza A virus resistance. On the other hand, Feng Li and colleagues provide an overview of pharmacological intervention of human immunodeficiency virus (HIV) maturation and HIV drug resistance. Increasing drug resistance and toxicities observed among many of the current approved HIV drugs post a need for developing anti-HIV agents with a safe profile and novel mechanism of action. Inhibition of HIV maturation has been identified as one of effective approaches to combat the drug resistance. HIV maturation is the final step of virus replication. In this review, the process of HIV maturation and current status of HIV maturation inhibitors are presented.

Finally, Li Niu provides a review on 2,3-benzodiazepine compounds. These compounds are designed to be noncompetitive antagonists for a better control of the activity of AMPA receptors. AMPA receptors are a group of ligand-gated ion channel receptors exclusively expressed in the central nervous system. Excessive activities of these receptors and/or elevated receptor expression play significant roles in a number of neurodegenerative disorders and diseases such as epilepsy, amyotrophic lateral sclerosis and stroke. Potent and selective 2,3-benzodiazepine AMPA receptor inhibitors, especially single subunit-selective inhibitors, may help improve efficacy and reduce side effects for these compounds when they are used as potential drugs for the treatment of these neurological diseases. Currently these compounds are a class of the most promising drug candidates targeting AMPA receptors.

I hope this issue provides our readers a comprehensive background and current views on the presented topics, and helps researchers in their search for effective therapeutic agents, as well as stimulates further research interests to move the fields forward.
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Professor Xiangming Guan is a tenured faculty in the Department of Pharmaceutical Sciences, South Dakota State University. Dr. Guan received his Bachelor׳s degree in Pharmacy from Zhejiang Medical University (now the College of Pharmaceutical Sciences of Zhejiang University) in China in 1982, and Ph.D. in Medicinal Chemistry in 1991 from University of Kansas, USA. Dr. Guan did one year postdoctoral training in the Department of Pharmaceutics, University of Kansas and continued his postdoctoral training in drug metabolism in the Department of Medicinal Chemistry, University of Washington before he joined the Department of Pharmaceutical Sciences at South Dakota State University in 1995 to start his independent research. He was tenured in 2000, promoted to Professor in 2005 and currently serves as the Assistant Dean for Research in the College of Pharmacy, South Dakota State University.

Dr. Guan׳s research is focused on developing agents/approaches of biomedical/pharmaceutical interests. His research group is characterized by touching various research disciplines that include drug design, organic synthesis, bioanalytical chemistry, enzymology, molecular biology, and drug metabolism. Currently, he is working on two major projects. One is to develop thiol specific fluorogenic reagents for thiol imaging and quantification in live cells through fluorescence microscopy. Due to the significant roles thiols play in various physiological/pathological functions, numerous analytical methods have been developed for thiol assays. However, none of those can be used for thiol imaging and quantification in live cells through fluorescence microscopy. Monitoring an analyte in live cells through fluorescence microscopy provides the advantage of allowing visualization of the analyte in its intact and native physiological environment and revealing the information that cannot be revealed by most other conventional analytical methods. Dr. Guan׳s group has identified a thiol specific thiol-sulfide exchange reaction. Based on this reaction, a number of thiol specific fluorogenic reagents have been developed. One of the reagents was developed as the first reagent able to image and quantify thiols in live cells through fluorescence microscopy. The reagent was later found to be capable of quantifying thiols in as low as 500 cells in a high throughput manner. The reagent is now named as GUALY׳s reagent and will be a valuable tool in exploring the roles of thiols in various thiol-related physiological/pathological conditions.

Another major project Dr. Guan׳s group is working on is to develop approaches to treat cancer metastasis by targeting the four essential steps (detachment, migration, invasion, and adhesion) in the metastasis process, especially the step of detachment. Despite extensive research efforts in the development of cancer therapeutic agents, agents for the treatment of cancer metastasis are limited. Dr. Guan׳s group has identified that glutathione disulfide (GSSG), when delivered properly, is able to not only effectively inhibit cancer growth but also block cancer metastasis through inhibition of cell detachment, migration, and invasion. Efforts in exploring the molecular targets of these effects and in developing GSSG as an effective therapeutic agent for the treatment of cancer growth and metastasis are under the way.

Dr. Guan has filed two patent applications, published two book chapters, and 32 peer-reviewed articles in prestigious journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry, Analytical Chemistry, Drug Metabolism and Disposition, Chemical Research in Toxicology, Free Radical Biology and Medicine, and Archives of Biochemistry and Biophysics. His research has been supported continuously by National Institutes of Health (NIH) since 1999.

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
